KSQ Therapeutics
Paige Graves has served as the Head of FP&A since June 2021. Paige has over 18 years experience in finance leadership roles within the biotech and life science industry. This experience has been supporting a variety of indications such as oncology/hematology, neurology and rare diseases. She joins KSQ from Epizyme where she led Financial Planning & Analysis. Previously, she served in roles of increasing responsibility at LFB USA, Synageva, Genzyme and Thermo Fisher Scientific focused on growing organizations, supporting commercial launches and building best in class FP&A function and processes. Paige received her MBA from Florida Atlantic University and a Bachelor of Business Administration in Accounting from Lynn University.
KSQ Therapeutics
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed.